FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2266666897> ?p ?o ?g. }

• W2266666897 endingPage "10" @default.
• W2266666897 startingPage "1005" @default.
• W2266666897 abstract "Recently, troglitazone has emerged as an insulin sensitizer for the treatment of type II diabetes. However, its effect on skeletal muscle glucose use (SMGU) has not been studied.To investigate the effect of troglitazone on SMGU in patients with type II diabetes, we undertook skeletal muscle (18)F-FDG PET dynamic imaging under insulin clamping before and after administration of SMGU to 20 patients with type II diabetes. Data were compared with those for 12 age-matched healthy volunteers.The whole-body glucose disposal rate (GDR) was significantly lower in patients (29.9 +/- 9.83 micromol/min/kg) than in control subjects (55.6 +/- 16.5 micromol/min/kg, P < 0.01), as was the SMGU (patients, 3.27 +/- 2.17 micromol/min/kg; control subjects, 10.9 +/- 6.4 micromol/min/kg; P < 0.01). After the therapy, GDR significantly improved in patients (29.3 +/- 14.6 micromol/min/kg, P < 0.05), as did SMGU (5.06 +/- 2.11 micromol/min/kg, P < 0.05). When results for patients with and without hypertension were separately analyzed, a significant improvement in SMGU after troglitazone was seen in both normotensive and hypertensive patients (normotensive [n = 10]: baseline, 3.67 +/- 2.89 micromol/min/kg; after therapy, 5.28 +/- 2.61 micromol/min/kg; P < 0.05; hypertensive [n = 10]: baseline, 2.89 +/- 1.22 micromol/min/kg; after therapy, 4.72 +/- 1.39 micromol/min/kg; P < 0.05). GDR in patients with and without hypertension was significantly improved by troglitazone (normotensive: baseline, 17.9 +/- 10.2 micromol/min/kg; after therapy, 31.9 +/- 15.9 micromol/min/kg; P < 0.01; hypertensive: baseline, 39.6 +/- 15.1 micromol/min/kg; after therapy, 47.7 +/- 23.8 micromol/min/kg; P < 0.05). The plasma free fatty acid concentration during insulin clamping was not changed by troglitazone (baseline, 1.1 +/- 0.86 mEq/L; after therapy, 0.93 +/- 0.65 mEq/L; P = not significant).Troglitazone can improve whole-body insulin resistance through the improvement of SMGU but not through a decline in plasma free fatty acid concentration in patients with type II diabetes with or without hypertension." @default.
• W2266666897 created "2016-06-24" @default.
• W2266666897 creator A5023817300 @default.
• W2266666897 creator A5025994244 @default.
• W2266666897 creator A5030974165 @default.
• W2266666897 creator A5049703919 @default.
• W2266666897 creator A5064335988 @default.
• W2266666897 creator A5067868993 @default.
• W2266666897 creator A5068538138 @default.
• W2266666897 creator A5072926650 @default.
• W2266666897 date "2001-07-01" @default.
• W2266666897 modified "2023-10-03" @default.
• W2266666897 title "Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients." @default.
• W2266666897 cites W14200900 @default.
• W2266666897 cites W1800570554 @default.
• W2266666897 cites W1833829642 @default.
• W2266666897 cites W1919085092 @default.
• W2266666897 cites W1955901897 @default.
• W2266666897 cites W1965240451 @default.
• W2266666897 cites W1968764560 @default.
• W2266666897 cites W1976160853 @default.
• W2266666897 cites W1976766119 @default.
• W2266666897 cites W2002031871 @default.
• W2266666897 cites W2010803961 @default.
• W2266666897 cites W2019390202 @default.
• W2266666897 cites W2036227669 @default.
• W2266666897 cites W2053990917 @default.
• W2266666897 cites W2059842910 @default.
• W2266666897 cites W2065569245 @default.
• W2266666897 cites W2066736958 @default.
• W2266666897 cites W2076863722 @default.
• W2266666897 cites W2083264131 @default.
• W2266666897 cites W2084243081 @default.
• W2266666897 cites W2092078486 @default.
• W2266666897 cites W2092274886 @default.
• W2266666897 cites W2106628250 @default.
• W2266666897 cites W2125090169 @default.
• W2266666897 cites W2138613751 @default.
• W2266666897 cites W2146406312 @default.
• W2266666897 cites W2156401392 @default.
• W2266666897 cites W2158145711 @default.
• W2266666897 cites W2163794208 @default.
• W2266666897 cites W2164471793 @default.
• W2266666897 cites W2170651583 @default.
• W2266666897 cites W2335922553 @default.
• W2266666897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11438619" @default.
• W2266666897 hasPublicationYear "2001" @default.
• W2266666897 type Work @default.
• W2266666897 sameAs 2266666897 @default.
• W2266666897 citedByCount "9" @default.
• W2266666897 countsByYear W22666668972012 @default.
• W2266666897 countsByYear W22666668972013 @default.
• W2266666897 crossrefType "journal-article" @default.
• W2266666897 hasAuthorship W2266666897A5023817300 @default.
• W2266666897 hasAuthorship W2266666897A5025994244 @default.
• W2266666897 hasAuthorship W2266666897A5030974165 @default.
• W2266666897 hasAuthorship W2266666897A5049703919 @default.
• W2266666897 hasAuthorship W2266666897A5064335988 @default.
• W2266666897 hasAuthorship W2266666897A5067868993 @default.
• W2266666897 hasAuthorship W2266666897A5068538138 @default.
• W2266666897 hasAuthorship W2266666897A5072926650 @default.
• W2266666897 hasConcept C126322002 @default.
• W2266666897 hasConcept C134018914 @default.
• W2266666897 hasConcept C170493617 @default.
• W2266666897 hasConcept C187345961 @default.
• W2266666897 hasConcept C2777180221 @default.
• W2266666897 hasConcept C2777391703 @default.
• W2266666897 hasConcept C2778150266 @default.
• W2266666897 hasConcept C2779306644 @default.
• W2266666897 hasConcept C2779959927 @default.
• W2266666897 hasConcept C555293320 @default.
• W2266666897 hasConcept C71924100 @default.
• W2266666897 hasConceptScore W2266666897C126322002 @default.
• W2266666897 hasConceptScore W2266666897C134018914 @default.
• W2266666897 hasConceptScore W2266666897C170493617 @default.
• W2266666897 hasConceptScore W2266666897C187345961 @default.
• W2266666897 hasConceptScore W2266666897C2777180221 @default.
• W2266666897 hasConceptScore W2266666897C2777391703 @default.
• W2266666897 hasConceptScore W2266666897C2778150266 @default.
• W2266666897 hasConceptScore W2266666897C2779306644 @default.
• W2266666897 hasConceptScore W2266666897C2779959927 @default.
• W2266666897 hasConceptScore W2266666897C555293320 @default.
• W2266666897 hasConceptScore W2266666897C71924100 @default.
• W2266666897 hasIssue "7" @default.
• W2266666897 hasLocation W22666668971 @default.
• W2266666897 hasOpenAccess W2266666897 @default.
• W2266666897 hasPrimaryLocation W22666668971 @default.
• W2266666897 hasRelatedWork W1968275340 @default.
• W2266666897 hasRelatedWork W2011642752 @default.
• W2266666897 hasRelatedWork W2046555760 @default.
• W2266666897 hasRelatedWork W2075561772 @default.
• W2266666897 hasRelatedWork W2095154144 @default.
• W2266666897 hasRelatedWork W2121536172 @default.
• W2266666897 hasRelatedWork W2133290655 @default.
• W2266666897 hasRelatedWork W2955051216 @default.
• W2266666897 hasRelatedWork W2965936516 @default.
• W2266666897 hasRelatedWork W3032077320 @default.
• W2266666897 hasVolume "42" @default.

• next